It was reported that the weight loss property (5-10%) of GLP-1 analogs is hampered by dose-dependent side-effects 10
My feet skidded to a halt, and my food-loving mind and sense of self bobbled forward and back
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Reduces inflammation: GHK-Cu possesses anti-inflammatory properties applicable to both wound sites and general skin health
76 GST prodrugs appear to have a more favorable adverse-event profile, given that they are ingested as an inactive compound and undergo breakdown to release cytotoxic metabolites only in the presence of high concentrations of enzymes that occur in the proximity of tumor cells, thereby reducing collateral damage to healthy cells
Based on these results, HMGCS2 and TFRC were selected for further validation (Supplementary Fig
.jpg)
